Mogo (NASDAQ:MOGO – Get Free Report) and Portage Biotech (NASDAQ:ALP – Get Free Report) are both small-cap technology companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, institutional ownership, earnings, valuation and profitability.
Institutional and Insider Ownership
14.8% of Mogo shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 12.3% of Mogo shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Volatility and Risk
Mogo has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.61, meaning that its stock price is 39% less volatile than the S&P 500.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| Mogo | 11.41% | 7.78% | 3.34% |
| Portage Biotech | N/A | N/A | N/A |
Earnings & Valuation
This table compares Mogo and Portage Biotech”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Mogo | $69.27 million | 0.38 | -$9.98 million | $0.23 | 4.74 |
| Portage Biotech | $100,000.00 | 39.71 | -$38.63 million | ($8.18) | -0.02 |
Mogo has higher revenue and earnings than Portage Biotech. Portage Biotech is trading at a lower price-to-earnings ratio than Mogo, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Mogo and Portage Biotech, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Mogo | 1 | 1 | 1 | 0 | 2.00 |
| Portage Biotech | 1 | 2 | 0 | 0 | 1.67 |
Mogo currently has a consensus target price of $4.00, suggesting a potential upside of 266.97%. Portage Biotech has a consensus target price of $0.25, suggesting a potential upside of 47.75%. Given Mogo’s stronger consensus rating and higher probable upside, equities analysts plainly believe Mogo is more favorable than Portage Biotech.
Summary
Mogo beats Portage Biotech on 13 of the 14 factors compared between the two stocks.
About Mogo
Mogo Inc. operates as a digital finance company in Canada, Europe, and internationally. The company's digital solutions help build wealth and achieve financial freedom. It provides MogoTrade, a stock trading app; Moka; and MogoMoney that provides online personal loans. The company also offers digital loans and mortgages; and operates a digital payments platform that powers next-generation card programs for both global corporations and fintech companies in Europe and Canada. Mogo Inc. is headquartered in Vancouver, Canada.
About Portage Biotech
Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.
Receive News & Ratings for Mogo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mogo and related companies with MarketBeat.com's FREE daily email newsletter.
